Lincoln Pharma launches Vitamin C+ Zinc tablets; stock gains two per cent

Healthcare company Lincoln Pharmaceuticals announced the launch of its Vitamin C+ Zinc tablets in Indian markets thus, consolidating its position in a market estimated at about Rs 150 crore in the country and growing at 15 per cent per annum.

The tablet is an evidence-based bio-active for natural immunity in a combination of zinc that boosts antiviral activity and protection against COVID-19. According to the company, the product launched will be in the form of a chewable tablet thus, benefitting pediatric and geriatric patients who may not have ready access to water.

Ashish R. Patel, Whole-Time Director of the company, while speaking on the launch, stated that with the launch, the company aims to fill the gaps in serving the healthcare requirement of the masses with its wide range of 600 plus formulations. He further stated that the company remains committed to fight the COVID-19 pandemic and working closely with the governments and relevant stakeholders to ensure uninterrupted supply of medicines.

Lincoln Pharmaceuticals Limited reported a standalone net profit of Rs 9.23 crore for Q4 ended March 2020, as against Rs 7.17 crore in the same quarter last year, showing a 29-per cent growth on a YoY basis. The company's standalone revenues for the quarter stood at Rs 81 crore, as against Rs 77 crore in the same quarter last year. For FY19-20, its net profit stood at Rs 50 crore as against Rs 47 crore in the previous year, reflecting a growth of about 6 per cent.

At 12.30 p.m. on Thursday, the stock of Lincoln Pharmaceuticals was trading at Rs 200.70, higher by 2.53 per cent or Rs 4.95 per share on BSE, against a 0.64 per cent gain in the benchmark index.